DRRX: Remoxy approved expected in 2H16, DUR-928 on track to enter into Phase II studies, Posimir Phase III initiated
Durect is a biopharmaceutical company with research and development programs. The company's product pipeline consists of various investigational drug candidates in development. DUR-928, a chemical entity in development, is a candidate in the company's Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. The company's proprietary oral and injectable delivery technologies include POSIMIR? (bupivacaine extended-release solution), an investigational analgesic product intended to deliver bupivacaine to provide up to three days of pain relief after surgery.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.